DSM421 is a dihydrodehydrogenase inhibitor (DHODH) that is in preclinical development as a potential treatment option for malaria and has shown activity against field isolates of both P. falciparum and P. vivax.

98%

Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution.

DMSO:10 mg/mL (27.91 mM)

DSM421, a dihydroorotate dehydrogenase inhibitor, was in preclinical development as a potential treatment option for malaria. When tested in a core battery of safety pharmacology assays, DSM421 did not produce any effects at oral doses up to 750 mg/kg in an Irwin test in rats, but a respiratory study in rats using head-out plethysmography resulted in substantial changes in respiratory function as well as moribundity and mortality at that and lower doses.[1]